Neo Ivy Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Neo Ivy Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,587	Closed	-$290K	–	678
2021 Q3	$290K	Buy	+2,587	New	+$475K	0.33%	111
2020 Q3	–	Sell	-2,587	Closed	-$290K	–	663
2020 Q2	$290K	Buy	2,587 +2,250	+668%	+$239K	0.33%	111
2020 Q1	$30K	Buy	+337	New	+$33.1K	0.05%	354
2019 Q4	–	Sell	-12,798	Closed	-$1.29M	–	426
2019 Q3	$1.29M	Buy	+12,798	New	+$1.44M	0.84%	1
2019 Q1	–	Sell	-6,581	Closed	-$641K	–	424
2018 Q4	$641K	Buy	+6,581	New	+$778K	0.5%	75

Other funds holding ALXN

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

Neo Ivy Capital Management's ALXN Position: Q4 2021 in Review

Neo Ivy Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2021, closing a stake of 2,587 shares — an estimated $290K sold.

Neo Ivy Capital Management first reported a position in ALXN in Q4 2018 and held it in 5 quarters. The position peaked at $1.29M in Q3 2019. 2 funds tracked by Wall St. Rank hold ALXN as of Q4 2021.

Neo Ivy Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Neo Ivy Capital Management sold 2,587 Alexion Pharmaceuticals shares in Q4 2021, an estimated $290K.
Neo Ivy Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 5 quarters.
Neo Ivy Capital Management's Alexion Pharmaceuticals position peaked at $1.29M in Q3 2019.
2 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2021.

Based on Neo Ivy Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.